Skip to main
TLX

TLX Stock Forecast & Price Target

TLX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Telix Pharmaceuticals has reported positive top-line results from a recent study, indicating additional potential for their radiopharmaceuticals in prostate cancer diagnosis, which could significantly enhance their U.S. revenue segment. In the second half of 2025, the company's precision medicine business generated $316 million, with sequential revenue growth driven by successful U.S. sales, reflecting strong execution and commercial performance. The potential approval of new agents for prostate cancer could expand the total addressable market by approximately $3.5 billion, further bolstering Telix's financial outlook.

Bears say

Telix Pharmaceuticals reported a net loss of $1.0 million, translating to an earnings per share (EPS) of $(0.30), which was worse than both internal estimates and consensus expectations. The company faces multiple risks that could negatively impact its future performance, including potential adverse clinical results for its lead asset TLX591, delays in advancing pipeline candidates, and challenges in obtaining timely regulatory approvals. Additionally, Telix is exposed to competitive pressures and long-term dilution risks, alongside balance sheet and liquidity concerns, which collectively contribute to a negative outlook for the stock.

TLX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Telix Pharmaceuticals Ltd (TLX) Forecast

Analysts have given TLX a Strong Buy based on their latest research and market trends.

According to 4 analysts, TLX has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Telix Pharmaceuticals Ltd (TLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.